Abstract: FR-PO0090
Protective Effects of Xuebijing on AKI in Patients with Community-Acquired Pneumonia
Session Information
- AKI: Epidemiology and Clinical Trials
November 07, 2025 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Acute Kidney Injury
- 102 AKI: Clinical, Outcomes, and Trials
Authors
- Chen, Dawei, Nanjing First Hospital, Nanjing, Jiangsu, China
- Wan, Xin, Nanjing First Hospital, Nanjing, Jiangsu, China
Background
Patients with community-acquired pneumonia (CAP) frequently suffer from acute kidney injury (AKI), which has a detrimental impact on both the long- and short-term prognosis. We will evaluate the potential protective effect of Xuebijing (XBJ) against AKI development in CAP patients.
Methods
In this retrospective cohort study, we analyzed 3468 adult CAP patients admitted between January 2014 and May 2017. Exclusion criteria included pre-existing AKI at admission, incomplete medical records, insufficient serum creatinine measurements (<2 tests), and regular dialysis or end-stage renal disease. Participants were stratified into two cohorts: XBJ recipients (n=413) and controls (n=3055). The primary outcome was AKI occurrence during hospitalization. We employed 1:1 propensity score matching (PSM) and inverse probability of treatment weighting (IPTW) to address confounding factors, supplemented by multivariate logistic regression and subgroup analyses.
Results
The cohort (median age 76 [IQR 61-83]; 59.3% male) demonstrated significant AKI risk reduction in XBJ recipients post-PSM (406 matched pairs). The XBJ group showed lower AKI incidence (11.1% vs. 19.0%; OR 0.53, 95% CI 0.36-0.79), with consistent findings in IPTW modeling (OR 0.60, 95% CI 0.42-0.84) and multivariate analysis (OR 0.55, 95% CI 0.36-0.77). Subgroup analyses confirmed robustness across demographic and clinical strata (interaction P-values 0.136-0.855). Notably, XBJ demonstrated stage-specific protection against AKI stage 1 (OR 0.49, 95% CI 0.29-0.82) and stage 2 (OR 0.33, 95% CI 0.15-0.76), though no significant association was observed with AKI stage 3 or renal replacement therapy requirements.
Conclusion
XBJ is associated with reduced AKI risk in CAP patients, particularly in early-stage renal injury. These findings position XBJ as a promising therapeutic intervention that may expand clinical options for AKI prevention in CAP management.
Association between XBJ and the occurrence of AKI in patients with community-acquired pneumonia.